• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Assessing ProAssurance (PRA) Valuation As Shares Hold Steady And Growth Expectations Moderate

    Simply Wall St·04/06/2026 02:18:25
    Listen to the news

    ProAssurance: Recent Returns and Business Mix

    ProAssurance (PRA) has drawn fresh attention after a steady share price near US$24.60, with total return over the past year at about 5.7% and the past 3 months at roughly 2.1%.

    For investors tracking income and profitability trends, ProAssurance reports annual revenue of about US$1.11b and net income of roughly US$50.9m, alongside reported annual revenue contraction of 3.2% and net income growth of 6.0%.

    The business is diversified across several insurance lines, which can matter for how earnings behave across cycles. Key revenue contributors are:

    • Specialty Property and Casualty, including Lloyd's syndicates, at about US$730.5m
    • Workers' Compensation Insurance at roughly US$166.4m
    • Segregated Portfolio Cell Reinsurance at around US$51.8m
    • Corporate and other activities at about US$150.4m, partly offset by US$1.1m of inter segment eliminations

    Within Specialty Property and Casualty, coverage focuses on healthcare providers and institutions, attorneys and law firms, and medical technology and life sciences companies. Workers' Compensation and alternative risk solutions extend the offering to a broader set of employers and risk managers.

    See our latest analysis for ProAssurance.

    The share price has been steady around US$24.60, and while the 1 day share price return of about 0.4% decline hints at softer near term momentum, the 1 year total shareholder return of roughly 5.7% alongside a 3 year total shareholder return near 31.9% points to a stronger longer term picture, despite a 5 year total shareholder return of about 7.8% decline.

    If you are comparing ProAssurance with other opportunities in insurance related or adjacent areas, it can help to expand your watchlist to companies with different growth drivers, balance sheets and risk profiles, including those highlighted in our 20 top founder-led companies

    With ProAssurance trading near US$24.60, only a small discount to its US$25.00 analyst price target and mixed long term returns, investors now face a key question: is there genuine upside left, or is the market already pricing in future growth?

    Most Popular Narrative: 8.5% Overvalued

    At a last close of $24.60 versus a narrative fair value of about $22.67, the most widely followed view sees ProAssurance as modestly overpriced in return for steadier, lower growth expectations and improving profitability.

    Analysts are assuming ProAssurance's revenue will decrease by 2.5% annually over the next 3 years.

    Analysts assume that profit margins will increase from 4.3% today to 7.0% in 3 years time.

    Read the complete narrative.

    The core of this narrative is a trade off: slower top line, richer margins, and a future earnings multiple that leans closer to quality growth than to deep value. Curious which revenue and margin paths have been stitched together to justify that price tag, and how much earnings power is being pencilled in a few years from now?

    Result: Fair Value of $22.67 (OVERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, this view still hinges on legal cost pressures and competitive pricing. Either factor could weaken margins and challenge the current fair value story.

    Find out about the key risks to this ProAssurance narrative.

    Next Steps

    The mixed messages on price and fair value make sentiment anything but clear, so it helps to move fast and weigh the evidence yourself. To see what optimism is built into the story and which potential upside the market is watching, review the 1 key reward

    Looking for more investment ideas?

    If ProAssurance has sharpened your thinking, do not stop here; use the Simply Wall St screener to quickly spot other opportunities that fit your objectives.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.